Vimarsana
Biggest News Aggregation in the World

Page 31 - Ir Team News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ir Team. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ir Team Today - Breaking & Trending Today

Junshi Biosciences Announces FDA Expanded Emergency Use - Vimarsana News

Junshi Biosciences Announces FDA Expanded Emergency Use

First and only neutralizing antibody therapy for this age group...

Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences Announces FDA Expanded Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Individuals under the Age of 12 - Vimarsana News

Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences Announces FDA Expanded Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Individuals under the Age of 12

Investegate announcements from Junshi Biosciences, Junshi Biosciences Announces FDA Expanded Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Individuals under the Age of 12

Junshi Biosciences Announces FDA Expanded Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Individuals under the Age of 12 - Vimarsana News

Junshi Biosciences Announces FDA Expanded Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Individuals under the Age of 12

First and only neutralizing antibody therapy for this age groupSHANGHAI, China, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical

Junshi Biosciences Announces Two Additional Indications for Toripalimab Included in China's National Reimbursement Drug List - Vimarsana News

Junshi Biosciences Announces Two Additional Indications for Toripalimab Included in China's National Reimbursement Drug List

--the only anti-PD-1 monoclonal antibody in the NRDL for melanoma and nasopharyngeal carcinomaSHANGHAI, China, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading

Junshi Biosciences Announces Two Additional Indications for Toripalimab Included in China's National Reimbursement Drug List - Vimarsana News

Junshi Biosciences Announces Two Additional Indications for Toripalimab Included in China's National Reimbursement Drug List

SHANGHAI, China, Dec. 03, 2021 -- Junshi Biosciences , a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel...